获得上海证券交易所受理的公告 公司本次向特定对象发行股票事项尚需上交所审核通过及中国证券监督管 理委员会（以下简称"中国证监会"）作出同意注册决定后方可实施，最终能 否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确定 性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注 意投资风险。 特此公告。 浙江圣达生物药业股份有限公司董事会 2023年8月16日 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603079 证券简称：圣达生物 公告编号：2023-035 浙江圣达生物药业股份有限公司（以下简称"公司"）于2023年8月15日收 到上海证券交易所（以下简称"上交所"）出具的《关于受理浙江圣达生物药 业股份有限公司沪市主板上市公司发行证券申请的通知》（上证上审（再融资 ）〔2023〕580号），上交所依据相关规定对公司报送的沪市主板上市公司发行 证券的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合 法定形式，决定予以受理并依法进行审核。 浙江圣达生物药业股份有限公司 ...

中信建投证券股份有限公司 关于 浙江圣达生物药业股份有限公司 向特定对象发行股票 之 上市保荐书 保荐人 二〇二三年八月 保荐人出具的上市保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人王站、王书言已根据《中 华人民共和国公司法》《中华人民共和国证券法》等法律法规和中国证监会及上 海证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规 则和行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 保荐人出具的上市保荐书 释 义 在本上市保荐书中，除非另有说明，下列词语具有如下特定含义 | 保荐人/中信建投证券 | 指 | 中信建投证券股份有限公司 | | --- | --- | --- | | 圣达生物/发行人/公司 | 指 | 浙江圣达生物药业股份有限公司 | | 本上市保荐书 | 指 | 中信建投证券股份有限公司关于浙江圣达生物药业股份 | | | | 有限公司向特定对象发行股票之上市保荐书 | | 股东大会 | 指 | 浙江圣达生物药业股份有限公司股东大会 | | 董事会 | 指 | 浙江圣达生物药业股份有限公司董事会 | | 人民币普通股、A股 | 指 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥169,278,694.33, representing a decrease of 8.58% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥3,491,046.45, down 83.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥768,830.17, a decline of 105.34%[5]. - The basic and diluted earnings per share were both ¥0.02, reflecting a decrease of 83.33%[6]. - The net profit for Q1 2023 was CNY 3,271,632.91, a significant decrease of 84.0% compared to CNY 20,395,348.28 in Q1 2022[22]. - The company achieved a total profit of CNY 5,575,375.89, down from CNY 23,676,663.82 in the same quarter last year[22]. - The company reported a net profit margin of approximately 0.75% for Q1 2023, compared to 9.0% in Q1 2022, indicating a decline in profitability[20]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥49,775,808.03, indicating a significant cash outflow[6]. - The company reported a net cash outflow from operating activities of CNY -49,775,808.03, worsening from CNY -11,335,230.05 in Q1 2022[24]. - Cash and cash equivalents as of March 31, 2023, were RMB 279,068,031.81, down from RMB 320,717,851.36 at the end of 2022, representing a decrease of 12.9%[17]. - Cash and cash equivalents at the end of Q1 2023 were CNY 260,029,482.88, down from CNY 296,238,667.03 at the end of Q1 2022[25]. - Investment activities resulted in a net cash outflow of CNY -57,724,177.90, compared to CNY -182,830,411.59 in Q1 2022[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,615,005,744.91, down 2.43% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,615,005,744.91, down from RMB 1,655,207,544.77 at the end of 2022, a decrease of 2.4%[19]. - Total liabilities decreased to RMB 268,288,501.34 from RMB 311,761,934.11, a reduction of 13.9%[19]. - The company's equity attributable to shareholders increased slightly to RMB 1,331,488,386.18 from RMB 1,327,997,339.73, an increase of 0.1%[19]. - Short-term borrowings were reduced to RMB 10,007,300.00 from RMB 32,642,669.33, a significant decrease of 69.4%[18]. Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 168,012,041.08, slightly up from RMB 167,206,511.12 in Q1 2022, indicating a marginal increase of 0.5%[20]. - The company incurred a total operating expense of CNY 230,012,747.88, an increase from CNY 196,570,365.22 in the previous year[24]. - Research and development expenses increased to CNY 9,192,182.34, up 27.7% from CNY 7,196,029.08 in Q1 2022[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,547[12]. - The company received government subsidies amounting to ¥4,235,086.52, which were included in the current period's profit[9]. Market Conditions - The decline in net profit was primarily due to the continuous decrease in vitamin product prices and rising raw material costs[10].

Financial Performance - The company achieved a net profit of CNY 5,913,119.37 in 2022, with a distributable profit of CNY 321,336,147.48 after statutory reserve and previous undistributed profits adjustments[7]. - The company's operating revenue for 2022 was RMB 738,019,050.08, a decrease of 6.55% compared to RMB 789,732,754.87 in 2021[25]. - The net profit attributable to shareholders for 2022 was RMB 31,486,120.69, down 58.44% from RMB 75,756,473.97 in the previous year[25]. - The basic earnings per share for 2022 was RMB 0.18, a decline of 59.09% from RMB 0.44 in 2021[27]. - The cash flow from operating activities for 2022 was RMB 40,717,546.99, a decrease of 45.32% compared to RMB 74,460,439.98 in 2021[25]. - The total assets at the end of 2022 were RMB 1,655,207,544.77, a decrease of 6.21% from RMB 1,764,814,096.10 at the end of 2021[26]. - The weighted average return on equity for 2022 was 2.38%, down 3.41 percentage points from 5.79% in 2021[27]. - The net profit after deducting non-recurring gains and losses for 2022 was RMB 10,691,488.19, a decrease of 79.25% from RMB 51,524,494.20 in 2021[25]. - The company reported a significant increase in financial expenses due to a rise in exchange gains, with a net financial expense of CNY -21.88 million, compared to CNY 8.87 million in the previous year[59]. Dividend Policy - A cash dividend of CNY 0.60 per 10 shares (including tax) is proposed for distribution to shareholders, pending approval at the 2022 annual general meeting[7]. - The company has outlined a three-year shareholder dividend return plan, aligning with regulatory requirements and long-term development needs[7]. - The total cash dividend amount for the reporting period was 10,271,337.48 RMB, representing 32.62% of the net profit attributable to ordinary shareholders[159]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, high customer concentration, exchange rate fluctuations, and changes in the macroeconomic environment[11]. - The company experienced a significant decline in sales revenue due to a drop in the price of its main product, biotin[27]. - The company has a high customer concentration risk, with the top five customers accounting for 21.09% of revenue in 2022[122]. - The company’s export revenue constituted 39.48% of its main business income in 2022, exposing it to exchange rate risks[122]. - Raw material price fluctuations significantly impact the company's profitability, as raw materials constitute a large portion of production costs[121]. Operational Highlights - The company has a 75% stake in Tongliao Shengda, a key subsidiary, which contributes to its operational capabilities[15]. - The company maintained a leading market share in its main products despite a challenging market environment[37]. - The subsidiary XinYinXiang achieved a sales growth of 18.53% and a net profit increase of 1.36% compared to the previous year[38]. - The company implemented cost reduction measures, achieving over 10% reduction in raw material procurement costs through innovative projects[38]. - The clean label product segment saw a significant revenue increase of 139.17%[37]. Research and Development - The company continues to invest in R&D, focusing on green catalytic technology and synthetic biology to enhance its technological capabilities[40]. - The company invested a total of RMB 37.81 million in R&D during the reporting period, with 28 ongoing projects and 5 national patents granted, including 4 invention patents[89]. - The number of R&D personnel is 160, accounting for 13.89% of the total workforce[74]. Governance and Compliance - The company emphasizes the importance of maintaining the authenticity and completeness of its financial reports, as confirmed by Tianjian Accounting Firm's standard unqualified audit report[6]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[5]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors and senior management, ensuring compliance with relevant laws and regulations[131]. - The company has maintained a governance structure that respects and protects the legitimate rights and interests of stakeholders, balancing the interests of shareholders, employees, and society[127]. Environmental Performance - The company reported a significant reduction in wastewater emissions from 307,509.938 tons in 2021 to 132,395 tons in 2022, indicating improved environmental performance[165]. - The company’s solid waste generation decreased from 990.81 tons in 2021 to 430.73 tons in 2022, reflecting enhanced waste management practices[165]. - The company maintains a daily wastewater treatment capacity of 520 tons, ensuring compliance with environmental standards[165]. - The company has established an environmental management system certified by ISO14001, ensuring stable operation of pollution control facilities[185]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion[132]. - The company plans to invest RMB 499.87 million in the first phase of the vitamin series products and raw materials upgrade project, expected to produce 220 tons of biotin and 1,000 tons of folic acid annually upon completion[99]. - The company aims to enhance product reserves and expand product applications through technological innovation and collaboration with research institutions[117]. - The company plans to enhance its market presence by expanding its environmental services to new regions and sectors[176].

证券代码：603079 证券简称：圣达生物 公告编号：2023-020 浙江圣达生物药业股份有限公司 关于召开2022年度业绩说明会的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 25 日（星期二）下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二)至 04 月 24 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@sd- pharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江圣达生物药业股份有限公司（以下简称"公司"）已于 2023 年 03 月 25 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况，公司计划于 2023 年 04 月 25 日下午 13 ...

Financial Performance - The company reported a net profit of CNY 5,913,119.37 for the year 2022, with a proposed cash dividend of CNY 0.60 per share[7]. - The total distributable profit for shareholders after accounting for legal reserves and previous undistributed profits is CNY 321,336,147.48[7]. - The company plans to allocate 10% of the net profit to statutory surplus reserves, amounting to CNY 591,311.94[7]. - The company's operating revenue for 2022 was RMB 738,019,050.08, a decrease of 6.55% compared to RMB 789,732,754.87 in 2021[25]. - The net profit attributable to shareholders for 2022 was RMB 31,486,120.69, down 58.44% from RMB 75,756,473.97 in the previous year[25]. - The basic earnings per share for 2022 was RMB 0.18, reflecting a decline of 59.09% from RMB 0.44 in 2021[27]. - The cash flow from operating activities for 2022 was RMB 40,717,546.99, a decrease of 45.32% compared to RMB 74,460,439.98 in 2021[25]. - The total assets at the end of 2022 were RMB 1,655,207,544.77, down 6.21% from RMB 1,764,814,096.10 at the end of 2021[26]. - The weighted average return on equity for 2022 was 2.38%, a decrease of 3.41 percentage points from 5.79% in 2021[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 10,691,488.19, down 79.25% from RMB 51,524,494.20 in 2021[25]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, and high customer concentration risk[11]. - The company experienced a significant drop in sales revenue due to a decrease in the price of its main product, biotin[27]. - Sales revenue from the top five customers accounted for 21.09% of total revenue in 2022, indicating a high customer concentration risk[122]. - The company's export revenue represented 39.48% of main business income in 2022, exposing it to foreign exchange risk due to reliance on USD for transactions[122]. - The vitamin industry is facing competitive pressure due to oversupply, but the company is positioned to leverage potential opportunities in 2023[42]. Subsidiaries and Investments - The company has a 75% stake in its subsidiary, Tongliao Shengda, which is a key part of its operations[15]. - The subsidiary XinYinXiang achieved a sales increase of 18.53% and a net profit growth of 1.36% compared to the previous year[38]. - The company’s subsidiary, New Silver Elephant, reported a revenue of 350.06 million RMB and a net profit of 35.78 million RMB in 2022[115]. - The company has a diverse portfolio of subsidiaries and associated companies, enhancing its market presence and operational capabilities[135]. Research and Development - The company is actively engaged in research and development, focusing on green catalytic technology and synthetic biology to support product development and technical support[40]. - The company invested CNY 37,810,800 in R&D during the reporting period, with 28 ongoing projects and 5 patents granted, including 4 invention patents[89]. - The company holds 5 national authorized patents, including 4 invention patents, reflecting its commitment to R&D and innovation[57]. - The company has established a strong talent development system, completing the introduction of four high-level talents at the national and provincial levels in 2022[40]. Environmental Performance - The company reported a significant reduction in wastewater emissions from 307,509.938 tons in 2021 to 132,395 tons in 2022, indicating improved environmental performance[165]. - The company maintained compliance with environmental standards for air emissions, with all reported pollutants meeting regulatory requirements[165]. - The company’s solid waste generation included 990.81 tons of distillation residues and 8,227 tons of sludge in 2022, reflecting ongoing waste management efforts[165]. - The company has established a dedicated environmental management department to oversee pollution prevention and compliance with environmental regulations[185]. - The company has implemented energy-saving measures and is actively managing carbon emissions, including the use of heat recovery technology[186]. Governance and Compliance - The company emphasizes the importance of maintaining the accuracy and completeness of its financial reports, as confirmed by its auditing firm[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not faced any violations in decision-making procedures regarding external guarantees[9]. - The company has established a transparent performance evaluation and incentive mechanism for its senior management[127]. - The company held three shareholder meetings in 2022, approving a total of 16 proposals, including the annual report for 2021 and the allocation of surplus funds for liquidity[129]. Market Strategy and Future Plans - The company is committed to long-term development while balancing immediate shareholder interests in its profit distribution plan[7]. - The company plans to invest approximately RMB 499.87 million in the first phase of the vitamin series product and raw material drug industry upgrade project, with an expected annual production of 220 tons of biotin and 1,000 tons of folic acid upon completion[99]. - The company aims to enhance production capacity for biological preservatives due to high demand, which has led to the abandonment of some clients[116]. - The company plans to strengthen its position in the synthetic biology industry by gradually expanding its technology base[118]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 150 million allocated for potential deals[132].

2022 年第三季度报告 证券代码：603079 证券简称：圣达生物 浙江圣达生物药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 185,468,824.03 | -2.17 | 535,910,347. ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching 500 million RMB, representing a 20% year-over-year growth[11]. - The company's operating revenue for the first half of 2022 was ¥350,441,523.13, a decrease of 10.17% compared to ¥390,135,440.81 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was ¥39,932,027.45, down 16.62% from ¥47,889,762.29 year-on-year[19]. - The basic earnings per share for the first half of 2022 was ¥0.23, a decline of 17.86% from ¥0.28 in the same period last year[20]. - The company reported a significant decline in sales volume of vitamin products, leading to reduced revenue and profit metrics[21]. - The company reported a net loss of CNY 59.92 million for the period, indicating a significant decrease in profitability[183]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% based on new product launches and market expansion strategies[11]. - Research and development efforts have led to the introduction of two new products in the biopharmaceutical sector, expected to contribute an additional 50 million RMB in revenue[11]. - The company is actively pursuing market expansion, targeting a 30% increase in market share in the next fiscal year through strategic partnerships and collaborations[11]. - The company is focusing on R&D innovation and expanding its product application areas to enhance customer loyalty and market competitiveness[32]. - The company plans to focus on market expansion and new product development in the upcoming quarters[162]. Financial Position and Cash Flow - The company has committed to maintaining a strong cash position, with cash reserves of 200 million RMB, ensuring liquidity for future investments[11]. - The net cash flow from operating activities decreased by 45.44% to ¥28,477,144.10, compared to ¥52,191,787.85 in the previous year[19]. - Cash and cash equivalents decreased significantly from ¥514,747,873.78 to ¥278,152,903.15, reflecting a decline of approximately 46%[155]. - The total cash and cash equivalents at the end of the period were CNY 252,806,779.74, down from CNY 348,596,797.29 at the end of the first half of 2021, reflecting a decrease of approximately 27.4%[171]. Research and Development - The company continues to focus on the research and development of biotin and biopreservation agents, maintaining its position as a major supplier in the global market[26]. - R&D investment increased by 1.72% year-on-year, emphasizing the company's commitment to innovation and technology development[45]. - The company has received 2 national invention patents and applied for 2 additional invention patents during the reporting period[40]. Environmental Compliance and Sustainability - The company has implemented a digital transformation in its procurement management through the introduction of ERP and BI systems, enhancing cost management[31]. - The company is actively promoting a green circular economy model, focusing on the reuse of by-products and continuous technological innovation[44]. - The company has established a commitment to protect investor interests, ensuring no misleading information in its IPO prospectus[96]. - The company has committed to continuous improvement in its environmental management practices[88]. Risk Management - The company faces risks including price fluctuations in raw materials, which could impact profit margins by up to 10% if not managed effectively[5]. - The management has emphasized the importance of diversifying the supply chain to mitigate risks associated with high customer concentration, which currently stands at 60%[5]. - The company has taken steps to reduce the impact of raw material price fluctuations on its operating performance through various operational strategies[61]. Shareholder Commitments and Governance - The company has committed to long-term shareholding intentions, with plans to gradually reduce holdings only after the lock-up period, adhering to regulatory requirements[95]. - The company guarantees that it and its controlled entities will not engage in any business that competes with its subsidiaries, both domestically and internationally[100]. - The company will publicly disclose reasons for any failure to fulfill commitments and will not engage in public refinancing during such periods[125].

Financial Performance - The company achieved a net profit of ¥39,592,789.63 in 2021, with a distributable profit of ¥339,980,794.17 after accounting for reserves and previous distributions[6]. - The company's operating revenue for 2021 was approximately ¥789.73 million, a decrease of 8.95% compared to ¥867.31 million in 2020[24]. - The net profit attributable to shareholders of the listed company was approximately ¥75.76 million, down 61.63% from ¥197.44 million in the previous year[24]. - The basic earnings per share for 2021 was ¥0.44, a decrease of 62.39% from ¥1.17 in 2020[25]. - The total revenue for the company was approximately $788.50 million, a decrease of 8.34% compared to the previous year[63]. - The gross profit margin for the main business was 28.84%, which represents a decrease of 26.03 percentage points year-over-year[63]. - The company reported a significant decline in the sales revenue of its main product, biotin, which was the primary reason for the decrease in financial metrics[25]. - The company's revenue for the reporting period was 789.73 million RMB, a decrease of 8.95% compared to the previous year, primarily due to a decline in biotin product sales prices[57][61]. Dividend and Profit Distribution - A cash dividend of ¥1.40 per 10 shares (including tax) is proposed for distribution to shareholders, pending approval at the annual general meeting[6]. - In 2021, the company distributed a total profit of 59,916,135.30 CNY, with a cash dividend of 3.50 CNY per 10 shares[158]. - The company has a three-year shareholder dividend return plan for 2021-2023, which was approved in April 2021[157]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, high customer concentration, exchange rate fluctuations, and external shocks from the pandemic[9]. - The global commodity price surge has increased production costs, impacting the overall profitability of the industry[39]. - The company is expected to face competitive pressure due to complex changes in the vitamin supply landscape in 2022[40]. - The company faces risks related to product price fluctuations due to market supply changes and raw material price volatility, which it aims to mitigate through increased environmental investment and capacity supply[122]. Market and Sales Performance - The quarterly revenue for Q4 2021 was approximately ¥210.02 million, showing a slight recovery compared to previous quarters[28]. - The sales volume of biotin increased by 30.02% year-on-year, and folic acid sales volume increased by 20.61%, marking the highest sales growth in five years[36]. - The lactic acid bacterium sales volume grew by 43.15%, with sales revenue increasing by 32.77%, while lysine sales volume surged by 90.47% and sales revenue rose by 44.93%[36]. - The domestic market achieved a main business revenue of 433 million RMB, an increase of 15.83% year-on-year, while the international market revenue was 355 million RMB, a decrease of 26.93%[57]. Research and Development - R&D investment increased by over 11% year-on-year, focusing on green catalytic technology and synthetic biology technology[37]. - The company invested ¥39,643,000 in R&D during the reporting period, with 42 ongoing projects and 6 patents granted, including 4 invention patents[92]. - The total R&D investment accounted for 5.02% of operating revenue, with no capitalized R&D expenditures[73]. - The company is focusing on technological innovation through collaboration with universities and research institutions, enhancing its competitive edge in the industry[91]. Supply Chain and Operational Efficiency - The company optimized its supply chain and production capacity, significantly increasing market share and brand influence despite challenges from raw material supply and price hikes[36]. - The company has adopted a "sales-driven production" model, optimizing procurement and production processes through digital transformation[50]. - The company is leveraging a digital supply chain and business intelligence systems to enhance decision-making and operational efficiency[51]. - The company reported a 24% reduction in logistics costs for Shengda Bio and a 13% reduction for New Silver Elephant through digital management and logistics control[37]. Environmental Responsibility - The company has established a robust framework for environmental responsibility, aligning with regulatory requirements and enhancing its operational practices[168]. - The company reported wastewater emissions of 98,519 tons in 2021, an increase from 87,334 tons in 2020, indicating a rise of approximately 13.4%[168]. - The company has implemented a comprehensive self-assessment and evaluation of its governance status, leading to improved operational awareness and governance levels[166]. - The company has established a complete wastewater treatment system that meets standards before discharging into the county's wastewater treatment plant[191]. Governance and Management - The company has maintained a governance structure that complies with relevant laws and regulations, ensuring transparency and accountability in operations[128]. - The independent directors have played a significant role in overseeing major company decisions, contributing to sound corporate governance practices[128]. - The company has established a performance evaluation and incentive mechanism for senior management, promoting transparency and fairness in management practices[128]. - The company has committed to timely and accurate information disclosure, ensuring all shareholders have equal access to company information[129].

Financial Performance - The company's operating revenue for Q1 2022 was ¥185,166,102.76, representing a decrease of 3.52% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥20,799,549.32, down 11.07% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥14,389,995.59, a decline of 25.22% compared to the previous year[5]. - The net profit for Q1 2022 was CNY 20,395,348.28, a decrease of 7.57% compared to CNY 22,063,598.84 in Q1 2021[22]. - The total profit for Q1 2022 was CNY 23,676,663.82, down from CNY 24,882,022.77 in the same period last year, reflecting a decline of 4.84%[22]. - Operating profit for Q1 2022 was CNY 23,531,335.07, compared to CNY 24,694,798.97 in Q1 2021, indicating a decrease of 4.69%[22]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥11,335,230.05, reflecting a significant decrease of 155.70%[5]. - Cash flow from operating activities showed a net outflow of CNY -11,335,230.05 in Q1 2022, contrasting with a net inflow of CNY 20,351,680.33 in Q1 2021[25]. - Cash and cash equivalents decreased to CNY 321,156,893.90 as of March 31, 2022, from CNY 514,747,873.78 at the end of 2021, a decline of 37.5%[16]. - Cash and cash equivalents at the end of Q1 2022 totaled CNY 296,238,667.03, down from CNY 391,247,468.23 at the end of Q1 2021[26]. - The total cash outflow from investing activities was CNY 218,711,963.09 in Q1 2022, compared to CNY 168,237,709.46 in Q1 2021, representing an increase of 30.06%[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,799,662,110.32, an increase of 1.97% from the end of the previous year[6]. - Total assets amounted to CNY 1,799,662,110.32, an increase from CNY 1,764,814,096.10 at the end of 2021, reflecting a growth of 2.0%[19]. - Total liabilities increased to CNY 442,295,269.44 from CNY 427,842,603.50, indicating a rise of 3.2%[18]. Shareholder Information - Basic and diluted earnings per share were both ¥0.12, down 14.29% from the same quarter last year[6]. - The company had a total of 17,100 common shareholders at the end of the reporting period[11]. - The company reported a basic and diluted earnings per share of CNY 0.12 for Q1 2022, down from CNY 0.14 in Q1 2021[22]. Operational Metrics - Total revenue for Q1 2022 was CNY 185,166,102.76, a decrease of 3.9% compared to CNY 191,930,642.69 in Q1 2021[20]. - Total operating costs for Q1 2022 were CNY 167,206,511.12, down from CNY 168,618,940.20 in Q1 2021, reflecting a slight reduction of 0.84%[20]. - Gross profit margin for Q1 2022 was approximately 9.5%, compared to 12.1% in Q1 2021, indicating a decline in profitability[20]. - Accounts receivable increased to CNY 155,019,748.61 from CNY 130,682,536.43, representing an increase of 18.6%[16]. - Inventory as of March 31, 2022, was CNY 266,760,488.09, up from CNY 222,087,972.31, marking an increase of 20.1%[17]. Future Outlook - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[20]. Expenses - The company experienced a 122.79% increase in selling expenses, attributed to higher bonus provisions during the period[10]. - The company incurred a credit impairment loss of CNY -1,568,940.87 in Q1 2022, compared to CNY -1,013,808.98 in Q1 2021, indicating a worsening of 55%[22].